ARTICLE | Product Development
Collaboration, standardization will bring access to convalescent plasma and answers about its efficacy
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 11, 2020 4:04 AM UTC
Academic institutions, companies and government agencies have added convalescent plasma to the growing list of interventions being brought under centralized protocols to treat COVID-19.
Large-scale, coordinated trials such as master protocols are gaining traction in the pandemic response as regulators suggest small studies won’t produce the data necessary to determine clinical efficacy (see “Coalition of Regulators Call Coordinated Trials Key”)...